PFAS in Pharmaceutical Packaging: Regulatory Landscape, Risk Mitigation, and Future-Proofing Your Supply Chain

Per- and polyfluoroalkyl substances (PFAS) are integral to many of the highest-performance materials in pharmaceutical parenteral packaging — including the fluoropolymer coatings (ETFE, PTFE, PCTFE) applied to elastomeric closures to minimize extractables and leachables, eliminate siliconization, and maintain container closure integrity (CCI) at ultra-low temperatures. The ECHA PFAS restriction proposal, submitted in January 2023 by Denmark, Germany, the Netherlands, Norway, and Sweden, is the broadest chemical restriction in EU regulatory history — encompassing approximately 10,000 substances under a chemical definition that includes both monomeric PFAS (widely recognized as bioaccumulative and harmful) and polymeric PFAS such as fluoropolymers (claimed by industry to be non-harmful). This on-demand webinar provides a structured technical and regulatory briefing on the PFAS landscape as it applies to pharmaceutical packaging. Topics covered include the chemical distinction between monomeric and polymeric PFAS and the industry's argumentation — supported by 5,600+ submissions to ECHA — for exempting fluoropolymers from the restriction; analytical testing methods for PFAS detection including LC/MS/MS, Combustion Ion Chromatography, Extractable Organic Fluorine (EOF), and Adsorbable Organic Fluorine (AOF) methods; the technical rationale for using coated components (reduced E/L, improved sterilization compatibility, better BL/GF profiles, 100% camera inspection); and Datwyler's scenario planning for two divergent regulatory outcomes — Scenario 1 (polymeric PFAS derogated/exempted, with additional production process requirements for fluoropolymer manufacturers) and Scenario 2 (full ban, requiring accelerated development of next-generation ultra-clean uncoated formulations and novel fluorine-free coatings).